TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32618115
Drug: COMBIND intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COMBIND intervention (specialized behavioural training plus a tablet-based mHealth application)
Study: 39696604
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) group
Study: 36028775
Drug: Individual nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual nutrition therapy (five in person visits and three phone calls) and freely delivered energy- and protein-rich foods
Study: 36028775
Drug: Individual nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual nutrition therapy
Study: 32812964
Drug: AOB‐w (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOB‐w (350 mg)
Study: 39566128
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment
Study: 34018342
Drug: Luvadaxistat 75
Normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luvadaxistat 75 mg BID
Study: 34018342
Drug: Luvadaxistat 300
Normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luvadaxistat 300 mg BID
Study: 35427363
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (3000 IU daily)
Study: 34985973
Drug: 15 to
Normalized name: ointment base no.215 TOPICAL OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 to 30 mg of arbaclofen (GABAB receptor agonist)
Study: 33041200
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of the first dose to the patient
Study: 33559294
Drug: Levofloxacin 750mg
Normalized name: LEVOFLOXACIN 750MG TAB
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 750mg once daily
Study: 33559294
Drug: Ciprofloxacin 400mg
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 400mg twice daily
Study: 34524953
Drug: Rescue intervention
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue intervention strategy (RIS) with budesonide/formoterol plus original treatment until severe pollution ended
Study: 34524953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained on original treatment
Study: 39547230
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT)
Study: 33573681
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 2% (20mg/mL)
Study: 33573681
Drug: Intravenous NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NaCl 0.9% (9 mg/mL)
Study: 34208986
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein snack (HP), n = 52, containing 50 g soybean
Study: 35597993
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care processes for antibiotic use and stewardship (control group)
Study: 34323589
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg gadoteridol at a rate of 3 mL/s (group A)
Study: 34323589
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg gadoteridol at a rate of 2 mL/s (group B)
Study: 32359021
Drug: Colloidal oatmeal
Normalized name: Colloidal Oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal oatmeal lotion (Aveeno™ Eczema Therapy Moisturizing Cream)
Study: 33208263
Drug: PEEK‐A (Ar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEK‐A (Ar cold plasma treatment)
Study: 33208263
Drug: PEEK‐N (N2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEK‐N (N2 cold plasma treatment)
Study: 33208263
Drug: PEEK‐AN (90%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEK‐AN (90% Ar and 10% N2 mixed cold plasma treatment)
Study: 32848380
Drug: tiotropium/olodaterol 5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium/olodaterol 5/5 µg
Study: 32969489
Drug: Dupilumab 2
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 2 mg kg−1
Study: 32969489
Drug: Dupilumab 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 4 mg kg−1
Study: 34268630
Drug: Single-crown restorations
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-crown restorations supported by short implants
Study: 34268630
Drug: Standard length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard length implants in conjunction with maxillary sinus floor augmentation (MSFA)
Study: 32064596
Drug: Topical rapamycin
Normalized name: natamycin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin 0.1%
Study: 33941638
Drug: High-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose corticosteroids and nebulised epinephrine for bronchiolitis
Study: 36217068
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (adding an anti‐staphylococcal beta‐lactam)
Study: 36217068
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin monotherapy)
Study: 32168290
Drug: Tablet-based Decision
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based Decision Support Tool (DST)
Study: 32429977
Drug: Oxytocin vaginal
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin vaginal gel (400 IU per night)
Study: 34671971
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (cryoprecipitate administered later or not at all)
Study: 34022880
Drug: Individualized surgery
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized surgery combined with radiotherapy and triamcinolone acetonide injection
Study: 34634368
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (FSGTC plus imrecoxib)
Study: 32697335
Drug: Glasdegib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib plus low-dose cytarabine (LDAC)
Study: 33001140
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of baricitinib once daily (n=111)
Study: 33001140
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of baricitinib once daily (n=109)
Study: 36581937
Drug: Non-invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive treatment
Study: 35982138
Drug: Low emotion
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low emotion control (L‐EC) training condition
Study: 33206131
Drug: Quadratus lumborum
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadratus lumborum block with spinal morphine
Study: 32506860
Drug: Thin wrist‐ankle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin wrist‐ankle acupuncture (WAA) + Fluoxetine
Study: 32506860
Drug: Thick wrist‐ankle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick wrist‐ankle acupuncture (WAA) + Fluoxetine
Study: 32506860
Drug: Sham wrist‐ankle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham wrist‐ankle acupuncture (WAA) + Fluoxetine
Study: 32646462
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (CFA) with 300 UI rFSH and 150 UI rLH in long agonist protocol
Study: 32646462
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (CFA) with 300 UI rFSH and 150 UI rLH in short antagonist protocol
Study: 35395080
Drug: Durvalumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab + low-dose bevacizumab (cohort B3)
Study: 33979451
Drug: Fenfluramine (FFA)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (FFA) at 0.4 mg/kg/day (n=2) or 0.7 mg/kg/day (n=4; maximum: 26 mg/day) for a mean duration of 5.3 months (range: 2–9 months)
Study: 36884013
Drug: D1 agonist
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 agonist
Study: 33658470
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement comprising 1197 mg of acetic acid bacteria containing 9.06 mg of ceramide
Study: 34925649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional therapy only)
Study: 35065705
Drug: SCB-2019 vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 vaccine (30 µg, adjuvanted with 1.50 mg CpG-1018 and 0.75 mg alum), administered as two 0.5 mL intramuscular doses 21 days apart.
Study: 35065705
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride for injection).
Study: 32683383
Drug: Ozonized water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonized water treatment
Study: 32683383
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (double‐distilled water)
Study: 32861358
Drug: Fascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy (3 weeks, 45 minutes per week)
Study: 34045486
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma containing high titers of neutralizing SARS‐CoV‐2 antibodies (300mL)
Study: 32041656
Drug: Intervention focusing
Normalized name: ficusin
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention focusing on both the individual and the household to enable self-management of treatment within an HIV competent household (Intervention)
Study: 34861374
Drug: Veliparib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib monotherapy (300-400 mg twice daily)
Study: 34861374
Drug: Veliparib during
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib during combination therapy and monotherapy
Study: 34861374
Drug: Veliparib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib and placebo monotherapy
Study: 36254693
Drug: empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin 10 mg once daily
Study: 33819498
Drug: Etomidate 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.03 mg/kg
Study: 33819498
Drug: Propofol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.2 mg/kg
Study: 33933353
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment, 2 sessions at 3-week intervals
Study: 33933353
Drug: Sham IPL
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham IPL treatment (Control)
Study: 33225554
Drug: Withdrawing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawing therapy
Study: 33225554
Drug: Withdrawing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawing therapy (non-randomized comparison)
Study: 33225554
Drug: Withdrawing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawing therapy (among those who did not relapse)
Study: 33225554
Drug: Withdrawing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawing therapy (in patients with TTN variants)
Study: 34959836
Drug: Shatavari (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shatavari (1000 mg/d for 6 weeks)
Study: 35662619
Drug: Reward Re‐Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reward Re‐Training (RRT) treatment for 10 weeks
Study: 32166429
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg weekly
Study: 33415859
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (nape seven needles combined with penetration needling for 30 min, once daily for 4 weeks)
Study: 33415859
Drug: Flunarizine hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine hydrochloride capsules (5 mg, once daily for 4 weeks)
Study: 33415859
Drug: Total effective
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total effective rate of treatment group
Study: 34762375
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (rehabilitation and hyperbaric oxygen)
Study: 34802087
Drug: Nomogram developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram developed based on multivariable logistic regression analysis using predictors such as glucocorticoid injection history, knee OA in the contralateral side, extensor muscle strength, area of cartilage deficiency, bone marrow lesion, and meniscus extrusion.
Study: 33574013
Drug: Double-headed capsule
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-headed capsule endoscopy (DH CE)
Study: 33574013
Drug: Single-headed capsule
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-headed capsule endoscopy (SH CE)
Study: 34309491
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate treatment (pamidronate, alendronate, ibandronate)
Study: 35924008
Drug: UDCA (13–15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (13–15 mg/kg/day) + fenofibrate (200 mg/day)
Study: 35924008
Drug: UDCA (13–15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (13–15 mg/kg/day)
Study: 34087055
Drug: Skin whitening
Normalized name: ASCORBYL GLUCOSIDE 1.5 g in 1 mg BUCCAL EMULSION [skin whitening]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin whitening serum containing niacinamide, hydroxyphenoxy propionic acid, dipotassium glycyrrhizate, glycolic acid, and 4‐n‐butylresorcinol applied twice daily combined with a spot‐preventing SPF50+ sunscreen
Study: 34781972
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine and perioperative gabapentin (ITM+GABA group)
Study: 34781972
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine only (ITM group)
Study: 32037134
Drug: internet‐based cognitive‐behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet‐based cognitive‐behavioural writing therapy (iCBT) for PTSD
Study: 34508547
Drug: DMARD tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMARD tapering arms
Study: 32736578
Drug: Brief Motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Motivational Treatment (BMT) - four 45-min sessions provided by a general psychologist with at least 3 years of primary care experience.
Study: 32736578
Drug: Brief Motivational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Motivational Treatment (BMT)
Study: 35279220
Drug: CO2-laser irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-laser irradiation in combination with fluoride therapy
Study: 35279220
Drug: Fluoride therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride therapy alone
Study: 34381108
Drug: EPA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (3 g/d)
Study: 34381108
Drug: DHA (3
Normalized name: Gesticare DHA (30) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (3 g/d)
Study: 34381108
Drug: High oleic
Normalized name: High Oleic Sunflower Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleic acid sunflower oil (3 g/day, baseline)
Study: 32609651
Drug: Pharmacological and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological and nonpharmacological treatments
Study: 32096902
Drug: Percutaneous Mastoid
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous Mastoid Electrical Stimulator (PMES) daily for 45 minutes for three months
Study: 32096902
Drug: Supraorbital Transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraorbital Transcutaneous Stimulator (STS) daily for 20 minutes for three months
Study: 32278346
Drug: Intramuscular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular glucocorticoid injection (40 mg triamcinolone acetonide)
Study: 34105200
Drug: Mass Drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Drug Administration (MDA)
Study: 32618245
Drug: focal Mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: focal Mass Drug Administration (fMDA)
Study: 33233020
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) intervention, 5-week escalating with reset; adjunct to standard smoking cessation treatment.
Study: 33233020
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation treatment (control group not explicitly detailed).
Study: 33658261
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention with weekly calls from registered dietitian nutritionists using motivational interviewing
Study: 34324700
Drug: Fremanezumab monthly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab monthly
Study: 35361446
Drug: Optimal guideline-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal guideline-directed medical therapy (GDMT) including beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and mineralocorticoid receptor antagonists
Study: 35361446
Drug: Optimal GDMT
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal GDMT triple therapy use
Study: 34088228
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of family old age care plus community old age care
Study: 34965635
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy with centrifugal exercise
Study: 32407535
Drug: MF59‐adjuvanted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐adjuvanted vaccine (FLUAD; Seqirus)
Study: 32407535
Drug: High‐dose vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High‐dose vaccine (Fluzone High‐Dose; Sanofi Pasteur)
Study: 32407535
Drug: Standard‐dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐dose inactivated influenza vaccine (FluQuadri; Sanofi Pasteur)
Study: 32407535
Drug: Recombinant hemagglutinin
Normalized name: Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen
DrugBank: Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen (DB14418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hemagglutinin vaccine (Flublok; Sanofi Pasteur)
Study: 37099983
Drug: Local estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local estrogen therapy
Study: 35797065
Drug: Motor imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor imagery combined with structured progressive circuit class therapy
Study: 35797065
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education combined with structured progressive circuit class therapy
Study: 33941192
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg every two weeks or 420 mg monthly)
Study: 32639688
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment only
Study: 35003321
Drug: Apixaban therapy
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban therapy (research group)
Study: 35003321
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation therapy (standard group)
Study: 33626041
Drug: Complex milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex milk lipid-enhanced (CML-E) group - same formulation enriched with complex milk lipids (≥8 mg gangliosides/day)
Study: 33626041
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - received standard powdered milk formulation (≥4 mg gangliosides/day)
Study: 34251840
Drug: Expectancy +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy + Drug (told active CBD - given active CBD)
Study: 34251840
Drug: Drug (told
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (told inactive - given active CBD)
Study: 32493111
Drug: Dorsal web
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal web space steroid injection
Study: 32493111
Drug: Palmar midline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmar midline steroid injection
Study: 34071868
Drug: Multi-ingredient pre-workout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient pre-workout supplement (MIPS)
Study: 34090765
Drug: 20% urea
Normalized name: UREA 20 g in 100 g TOPICAL CREAM [Nekvnro 20% Urea Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% urea cream